Welcome to our dedicated page for Earth Science Te news (Ticker: ETST), a resource for investors and traders seeking the latest updates and insights on Earth Science Te stock.
Earth Science Tech, Inc. reports news on its role as a diversified healthcare and wellness holding company with OTC-traded common stock. Recurring updates cover its compounding pharmacy operations, including RxCompoundStore.com and Mister Meds, and telemedicine platforms such as Peaks Curative, DOConsultation, MOCTeledoc and MyOnlineConsultation.com.
Company announcements also address financial results, public-company governance, auditor and investor-relations changes, industry-classification updates, FINRA quotation clearance, and portfolio activity outside healthcare through Avenvi real estate and asset management and MagneChef direct-to-consumer products.
Earth Science Tech (OTC: ETST) has acquired Meduvo LLC, a La Verne, California-based compounding pharmacy, creating a strategic West Coast hub and expanding its pharmacy network to 34 U.S. jurisdictions. Regulatory approvals for additional states are being pursued to move toward nationwide dispensing coverage.
Meduvo currently operates from a 2,000-square-foot facility focused on non-sterile compounded medications. According to Earth Science Tech, the company plans facility upgrades to meet sterile compounding standards and is targeting full regulatory certification for sterile compounding by the end of 2028, supporting its vertically integrated health and wellness platform.
Earth Science Tech (OTC: ETST) reported fiscal first quarter 2027 results for the period ended June 30, 2026. Revenue rose to $9.0 million from $8.8 million, while net income increased 57% to $715,697. Diluted EPS more than tripled to $0.003 from $0.001.
Net cash provided by operating activities grew 108.4% to $707,131. Total assets reached $10.4 million, up from $7.8 million a year earlier. The company repurchased and retired over 3.7 million shares of common stock, compared to 505,000 in the prior-year quarter, without adding debt. All key operating subsidiaries were profitable, supported by expanding compounding pharmacy licensing and ongoing evaluation of opportunities in telehealth and pharmacy fulfillment.
Management plans to discuss these results and strategic initiatives, including proposed cancellation of Series B preferred stock and evaluation of a potential exchange uplisting, at the Annual Meeting on August 31, 2026.
Earth Science Tech (OTC: ETST) reported full-year results for fiscal 2026 ended March 31, 2026. Revenue was $35.7 million (+8%), gross profit $25.5 million (+5%), and net income $3.6 million (+11%). Total assets rose to $9.0 million (+27%).
The company generated positive operating cash flow, added no new debt, and repurchased and retired 4.0 million shares in fiscal 2026 and over 3.1 million shares in fiscal Q1 2027, supporting its shareholder value strategy.
Earth Science Tech (OTC: ETST) released its annual shareholder letter for the fiscal year ended March 31, 2026. The company highlights cash flow positive operations across its platform, segment reporting changes, and debt-free expansion.
Key milestones include share repurchases, Health/Wellness growth, and Peaks Curative revenue surpassing $2 million in the first week of fiscal Q4 2026.
Earth Science Tech (OTC:ETST)/b) announced that CEO and Chairman Giorgio R. Saumat will present at the .
The presentation is scheduled for Wednesday, June 17, 2026, at 9:00 a.m. PT / 12:00 p.m. ET at the Bellagio Resort & Hotel and will include a live Q&A and one-on-one investor meetings.
Earth Science Tech (OTC: ETST) launched MyOnlineConsultation.com via MOCTeledoc, LLC, completing a vertically integrated telehealth-to-pharmacy ecosystem on March 24, 2026.
MOCTeledoc exited beta as cash-flow-positive and management projects it will become a meaningful revenue stream alongside ETST's compounding and DTC divisions, which reported $25.9 million revenue for the nine months ended December 31, 2025.
Earth Science Tech (OTC: ETST) announced strategic portfolio, governance and capital-discipline initiatives aimed at positioning the company as an institutional-ready public company.
Management reported $3.3M net income for fiscal 2025 and expects approximately $1.4M in annualized cost savings for fiscal 2026, supporting an anticipated ~40%+ net income increase to $4.7M on a go-forward basis.
Key steps include divesting non-core assets, consolidating subsidiaries, introducing advisory shareholder votes (including say-on-pay and Series B retirement), executives voiding employment contracts to reduce costs, and reduced board compensation.
Earth Science Tech (OTC: ETST) engaged Semple, Marchal & Cooper, LLP as its new independent PCAOB auditor on Feb. 17, 2026 to upgrade audit capabilities and governance.
The company cited rising consolidated accounting complexity across pharmacy compounding, telemedicine and real estate and said the regional firm’s broader resources and specialized expertise will optimize auditing efficiencies and better match ETST’s current operational scale.
Earth Science Tech (OTC: ETST) reported Q3 fiscal 2026 results for the quarter ended December 31, 2025, with revenue of $8.4M (+14.1% YoY) and net income of $910K (+341% YoY). Gross profit rose $1.3M to $6.4M (76.3% margin). Adjusted EBITDA was $1.2M. Cash on hand fell to $416K as inventory and operations increased. The company reported Peaks telemedicine revenue surpassing $2.0M in under a year and repurchased shares during the period.
Earth Science Tech (OTC: ETST) will release financial results for the three months ended December 31, 2025 after the close of trading on Tuesday, February 17, 2026. Investors may submit questions in advance and listen via conference call or live webcast.
Conference call is scheduled for 5:00 p.m. Eastern on February 17, 2026, with toll‑free and international dial‑in numbers, passcode, and replay webcast links provided for investor access.